New Coronado division Checkpoint licenses antibodies from Dana-Farber
Coronado Biosciences Inc. created a new division, Checkpoint Therapeutics Inc., which has been tasked with developing a handful of preclinical immuno-oncology antibodies in-licensed from the Dana-Farber Cancer Institute.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.